News

The Shanghai Canbi news column provides information on reference preparations, pharmaceutical intermediates, development of pharmaceutical raw materials and blood products in the field of biomedicine. Access to the latest and most comprehensive medical news policies through various global medical news platforms, collect the latest medical research and development data, take you to understand the latest trends and policies of the pharmaceutical industry, stay at home to read the latest global medical news and information.

• 
  UBIX THERAPEUTICS KICK OFF AN IND-ENABLING STUDIS OF BRUTON’S TYROSINE KINASE DEGRADER
  Seoul, Republic of Korea – July 20th, 2021 – South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead program, UBX-303, which utilizes Ubix’s platform technology, Degraducer®. UBX-303 is a Br
  Tags：
  The number of readers：1073
  Source：
  2021-07-20
• 
  US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness
  The US Food and Drug Administration (FDA) has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients 6 years of age and older and weig
  Tags：
  The number of readers：1076
  Source：
  2021-07-19
• 
  KEYTRUDA®(pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadju
  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522. The trial investigated neoadjuvant KEYTRUDA, Merck’s anti-PD-1
  Tags：
  The number of readers：877
  Source：
  2021-07-16
• 
  Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
  Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi®) resulted in significantly improved outcomes in
  Tags：
  The number of readers：835
  Source：
  2021-07-15
• 
  Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
  Suzhou Kintor Pharma Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IN
  Tags：
  The number of readers：1001
  Source：
  2021-07-14
• 
  CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
  keso Biopharma Inc.. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia. AK117 resulted
  Tags：
  The number of readers：1072
  Source：
  2021-07-13
• 
  U.S. FDA Grants Regular Approval and Expands Indication for PADCEV®(enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
  Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug Administration (FDA) granted PADCEV® (enfortumab vedotin-ejfv) regular approval in the U.S., i
  Tags：
  The number of readers：1064
  Source：
  2021-07-12
• 
  ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A
  ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Dr
  Tags：
  The number of readers：909
  Source：
  2021-07-08
• 
  EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06
  EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients
  Tags：
  The number of readers：991
  Source：
  2021-07-07
• 
  GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
  GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders,
  Tags：
  The number of readers：975
  Source：
  2021-07-05

Product Info

Product Name

Synonyms

CAS

Molecular Formula Upload

Contact Us

Company

Name

Tel

Email

Details

Submit

• Please fill in product name !
• CAS
• Please fill in your company information correctly!
• Please fill in liaison information correctly!
• Please fill in your telephone number correctly!
• Please fill in your email correctly!
• Please describe the problem of products!